W Polsce: Rekrutacja zakończonaNa świecie: RekrutujeFaza II/III
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast…
Miasta: Biała Podlaska, Opole, Skórzewo, Warszawa i 1 inne miastoWiek: od 18 latSponsor: Bristol-Myers Squibb Services Unlimited Company
RekrutujeFaza III
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With…
Miasta: Biała Podlaska, Białystok, Kraków, Poznań i 1 inne miastoWiek: od 18 latSponsor: Jazz Pharmaceuticals Ireland Limited
RekrutujeFaza III
Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0…
Miasta: Biała Podlaska, Koszalin, Lublin, Poznań i 3 inne miastaWiek: od 18 latSponsor: AstraZeneca AB
RekrutujeFaza III
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1…
Miasta: Biała Podlaska, Gliwice, Kraków, Poznań i 2 inne miastaWiek: od 18 latSponsor: Leonabio Inc.